Leadership Transition - Polpharma Group announces a leadership transition with Markus Sieger stepping down as CEO effective January 1, 2026, after ten years of service [1] - Sebastian Szymanek has been appointed as the new CEO, also effective January 1, 2026, currently serving as President of the Management Board of Zakłady Farmaceutyczne Polpharma S.A. in Poland [3][4] Company Growth and Mission - Under Markus Sieger's leadership, Polpharma Group has achieved significant financial growth and has focused on its mission to provide high-quality, affordable medicines to millions of patients [2] - The company has established itself as a trusted partner to healthcare systems across Europe and Central Asia [2] Leadership Experience - Sebastian Szymanek brings nearly 30 years of experience in the pharmaceutical industry, having joined Polpharma in 2007 and held various key leadership roles [4] - His tenure includes serving as General Manager for Poland and leading Zakłady Farmaceutyczne Polpharma S.A. since September 2021 [4][5] Strategic Vision - Nick Haggar, Chairman of the Supervisory Board, expressed confidence in Sebastian Szymanek's ability to lead Polpharma Group into its next chapter, citing his deep knowledge of the organization and commitment to its mission [5] Company Overview - Polpharma Group is a leading regional manufacturer of pharmaceuticals, active in Central and Eastern Europe, the Caucasus, and Central Asia, producing 400 million packages of medicines annually [6] - The Group employs 5,600 people and operates in over 40 countries, offering modern medicines and innovative solutions [6]